Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company’s major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients.
Paragraph 17 of the Agreement addressed controversies or disputes and provided that “[a]ny controversy or dispute arising out of or relating to this . . . [Agreement], or the interpretation thereof, shall be settled exclusively by arbitration . . . .” The Agreement afforded plaintiff twenty-one days to review its terms and conditions and provided that if it was not executed by the twenty-first day, the Agreement would automatically expire on the twenty-second day following plaintiff’s receipt of the Agreement.